Better Health for All

SCYNEXIS's core business is dedicated to developing innovative antifungal drugs, such as ibrexafungerp and SCY-247, which address significant unmet therapeutic needs, including drug-resistant pathogens like *Candida auris* with high mortality rates.

Clinical trials for ibrexafungerp in acute vulvovaginal candidiasis demonstrated a 63.3% clinical cure rate compared to 44.0% for placebo, indicating substantial health benefits. The company has no reported revenue from products with negative health outcomes. However, SCYNEXIS experienced a product recall for BREXAFEMME due to potential beta-lactam cross-contamination and an FDA clinical hold on ibrexafungerp trials, although the hold was lifted in late April 2025. The company discloses potential cross-contamination risks, product recalls, and litigation. While the company holds patents for its products, there is no evidence regarding its flexibility or access frameworks for these patents. Clinical trials are conducted in accordance with GCP requirements, including informed consent, and ethics approvals were obtained for studies.

Fair Money & Economic Opportunity

SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing anti-infectives.

The provided articles detail its financial performance, product development, regulatory approvals, and licensing agreements for pharmaceutical products. There is no evidence in the articles that SCYNEXIS offers lending, deposit, or other financial services to consumers or businesses. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's core business model, and no relevant data was found to assess these metrics beyond the 'not applicable' tier.

Fair Pay & Worker Respect

The company has no public record of substantiated labor-law or human-rights violations.

While a securities class action lawsuit was filed on November 7, 2023, alleging misstatements regarding manufacturing controls, this case was dismissed with prejudice on August 29, 2025. Related shareholder derivative complaints filed on May 1, 2024, and June 4, 2024, were consolidated and dismissed without prejudice on October 15, 2025. These lawsuits do not constitute substantiated labor-law or human-rights violations. An amendment to an employment agreement addressed concerns about potential tax penalties under the Affordable Care Act to ensure compliance, rather than indicating a substantiated violation.

Kind to Animals

SCYNEXIS conducts animal testing as part of its research and development activities for compounds such as SCY-078 and SCY-247.

The company's policy is to conduct animal testing in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare, with studies receiving IACUC approval. The company acknowledges that its R&D activities could be affected by restrictions on animal testing. In a murine model study for SCY-247, a total of 601 female BALB/c mice were used.

No War, No Weapons

SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing antifungal agents. The provided articles, primarily financial reports and company announcements, consistently state that there is no mention or applicability of arms or defense contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, defense-related board oversight, export certifications, defense-related lobbying, humanitarian procurement standards, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance contracts, ethical red lines for weapons, exposure to controversial weapons, war-related supply chain risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, procurement from conflict zones, or ethical red line compliance rates.

The company's business model is entirely centered on pharmaceutical development.

Safe & Smart Tech

The company has no reported data breaches or incidents of unauthorized data use.

There is no mention of any regulatory actions, violations, fines, or compliance issues specifically related to cybersecurity. The company states it encrypts "certain data," which is considered standard practice without further detail on scope or strength.

Zero Waste & Sustainable Products

SCYNEXIS, Inc. participates in a Product Stewardship Plan for household pharmaceutical waste in San Mateo County.

This plan provides comprehensive take-back options, including 52 kiosk drop-off sites and mail-back services available to all residents, covering a near-universal percentage of products within this regional scope. The plan aims to collect an estimated average of 100 pounds of unwanted medicine per kiosk annually and reach 50% of the adult population through media outreach by the end of 2025. The company's hazardous waste management includes the destruction of recalled BREXAFEMME product with an experienced vendor and adherence to detailed procedures for the collection, transportation, and disposal of unwanted medicines as hazardous waste, primarily through permitted incinerators. Vendor performance for the waste management plan is verified via periodic audits and annually for major facilities. The company has not incurred any waste disposal violations in the past three years; however, the disposal facilities used by the plan have received fines ranging from $20,000 to $330,000 for various environmental violations. The plan includes extensive educational and outreach programming, with over 43,000,000 impressions, to inform residents about proper disposal. Suppliers (vendors) for the plan must follow all applicable laws, regulations, and other legal requirements.